Prothena | PRTA - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Akebia Therapeutics USD 32.61M 8.98M 2025-12
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Exelixis USD 2.16B 619K 2025-12
Immunic USD 10.5M 23.41M 2025-09
Incyte USD 5.17B 516.28M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
MacroGenics USD 55.59M 11.41M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Prothena USD 280.47M 14.51M 2025-12
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12
Xoma USD 87.94M 15.5M 2025-09